Nova Eye Medical (EYE.AX) Stock Price
Nova Eye Medical Price
Revenue at Nova Eye Medical has contracted by 7.3% per year over the past 10 years to 29.27 M AUD. Earnings per share have grown at 73.9% per year over the last 5 years. Nova Eye Medical's net margin stands at -31.0%, broadly stable from -32.0% several years earlier. Nova Eye Medical currently offers a dividend yield of about 2.07%. The payout ratio is around 1% of earnings. Analysts set a median price target of 0.51 AUD, implying 264.3% above the current price. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus. The stock trades about 40% above its 52-week low.
Nova Eye Medical stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Nova Eye Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Nova Eye Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Nova Eye Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Nova Eye Medical Price |
|---|---|
| 9/11/2026 | 0.14 AUD |
| 9/10/2026 | 0.14 AUD |
| 9/9/2026 | 0.14 AUD |
| 9/8/2026 | 0.14 AUD |
| 9/7/2026 | 0.14 AUD |
| 9/4/2026 | 0.14 AUD |
| 9/3/2026 | 0.14 AUD |
| 9/2/2026 | 0.13 AUD |
| 9/1/2026 | 0.14 AUD |
| 8/31/2026 | 0.14 AUD |
| 8/28/2026 | 0.14 AUD |
| 8/27/2026 | 0.14 AUD |
| 8/26/2026 | 0.14 AUD |
| 8/25/2026 | 0.14 AUD |
| 8/24/2026 | 0.14 AUD |
| 8/21/2026 | 0.14 AUD |
| 8/20/2026 | 0.14 AUD |
| 8/19/2026 | 0.14 AUD |
| 8/18/2026 | 0.14 AUD |
| 8/17/2026 | 0.14 AUD |
| 8/14/2026 | 0.14 AUD |
| 8/13/2026 | 0.16 AUD |
| 8/12/2026 | 0.16 AUD |
| 8/11/2026 | 0.16 AUD |
| 8/10/2026 | 0.16 AUD |
| 8/7/2026 | 0.16 AUD |
| 8/6/2026 | 0.14 AUD |
| 8/5/2026 | 0.14 AUD |
| 8/4/2026 | 0.14 AUD |
| 8/3/2026 | 0.13 AUD |
Nova Eye Medical Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Nova Eye Medical Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM AUD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM AUD |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.00 | 72.00 | 71.00 | 79.00 | 16.00 | 12.00 | 13.00 | 13.00 | 17.00 | 23.00 | 29.00 | 34.00 | 42.00 | 51.00 | 62.00 |
| – | 16.13 | -1.39 | 11.27 | -79.75 | -25.00 | 8.33 | – | 30.77 | 35.29 | 26.09 | 17.24 | 23.53 | 21.43 | 21.57 |
| 51.61 | 56.94 | 56.34 | 58.23 | 81.25 | 75.00 | 84.62 | 84.62 | 82.35 | 86.96 | 62.07 | 62.07 | 62.07 | 62.07 | 62.07 |
| 32.00 | 41.00 | 40.00 | 46.00 | 13.00 | 9.00 | 11.00 | 11.00 | 14.00 | 20.00 | 18.00 | 21.10 | 26.07 | 31.66 | 38.48 |
| 2.00 | 4.00 | -1.00 | -5.00 | -8.00 | -7.00 | -4.00 | -9.00 | -11.00 | -8.00 | -8.00 | -4.00 | -1.00 | 3.00 | – |
| 3.23 | 5.56 | -1.41 | -6.33 | -50.00 | -58.33 | -30.77 | -69.23 | -64.71 | -34.78 | -27.59 | -11.76 | -2.38 | 5.88 | – |
| 1.00 | 3.00 | – | -5.00 | -5.00 | 35.00 | -4.00 | -7.00 | -15.00 | -8.00 | -9.00 | -3.00 | -1.00 | 1.00 | – |
| – | 200.00 | – | – | – | -800.00 | -111.43 | 75.00 | 114.29 | -46.67 | 12.50 | -66.67 | -66.67 | -200.00 | – |
| 107.65 | 109.14 | 118.05 | 134.39 | 143.60 | 143.60 | 147.52 | 148.54 | 160.17 | 204.14 | 247.33 | 247.33 | 247.33 | 247.33 | 247.33 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Nova Eye Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Nova Eye Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Nova Eye Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Nova Eye Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Nova Eye Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Nova Eye Medical stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Nova Eye Medical Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Nova Eye Medical business model & stock analysis
Nova Eye Medical SWOT Analysis
Strengths
- Nova Eye Medical Ltd is a leading company in the ophthalmic medical device industry.
- The company has a strong and experienced management team with deep industry knowledge.
- Nova Eye Medical's products are advanced and innovative, giving them a competitive edge in the market.
Weaknesses
- The company heavily relies on a few key products, making it vulnerable to market fluctuations and competition.
- Nova Eye Medical has limited geographical presence, which restricts its market reach.
- The high cost of Nova Eye Medical's products may limit their accessibility in certain markets.
Opportunities
- The global ophthalmic medical device market is growing rapidly, providing opportunities for Nova Eye Medical to expand its customer base.
- Increasing awareness about eye health and advancements in technology create a favorable environment for the company's innovative products.
- Strategic partnerships or collaborations with other companies can enhance Nova Eye Medical's market presence and product offerings.
Threats
- Intense competition from established players in the industry poses a threat to Nova Eye Medical's market share.
- Regulatory changes or stringent approval processes for medical devices can impact the company's ability to introduce new products.
- Economic downturns or financial instability in key markets may affect the demand for Nova Eye Medical's products.
Nova Eye Medical Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Nova Eye Medical historical P/E ratio, EBIT multiple, and P/S ratio
Nova Eye Medical annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Nova Eye Medical shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Nova Eye Medical stock splits
Nova Eye Medical Dividend History
2 years of dividend payments
Nova Eye Medical dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Nova Eye Medical forecasts and price targets in September 2026
Analyst Price Targets 2026Nova Eye Medical Earnings Calls
Nova Eye Medical shareholder structure
| % | Name |
|---|---|
0.53042% |
Nova Eye Medical Beneficial Ownership Filings (SEC 13D/G)
Nova Eye Medical Executives and Management Board
6 members · avg. age 58 · 0 % women
Mr. Thomas Spurling
Managing Director, Executive Director · since 2011
310,578.00 AUD
Management
Mr. Simon Gray
Company Secretary
Board of Directors
Mr. Victor Previn
Executive Chairman of the Board · since 2001
Mr. Rahmon Coupe (58)
Non-Executive Independent Director
Mr. Michael Southard
Non-Executive Director · since 2018
Mr. Daniel Webb
Independent Director
Frequently asked questions about Nova Eye Medical
The business model of Nova Eye Medical Ltd is focused on developing and commercializing innovative medical devices for the treatment of eye diseases. Their flagship product, the iTrack™ Microcatheter, is designed to provide a minimally invasive treatment option for patients with glaucoma. Nova Eye Medical Ltd aims to improve patient outcomes and enhance the efficiency of procedures through their advanced technology. By offering a range of surgical devices and solutions, they contribute to the advancement of ophthalmic care. Nova Eye Medical Ltd's commitment to innovation and their dedication to addressing the needs of the ophthalmology field make them a leading player in the industry.
Nova Eye Medical Ltd is primarily active in the ophthalmic medical device industry.
The main competitors of Nova Eye Medical Ltd in the market include companies such as Alcon, Johnson & Johnson Vision, and Bausch + Lomb.
Nova Eye Medical Ltd is an Australian-based medical technology company specializing in the development and commercialization of innovative ophthalmic devices. Founded in 2003, Nova Eye Medical has established itself as a key player in the ophthalmic market, offering advanced solutions for a range of eye conditions. The company's flagship product, the iTrack™ Surgical System, stands out for its effectiveness in glaucoma treatment. With a commitment to improving patient outcomes and advancing ophthalmic care, Nova Eye Medical continues to make significant contributions to the field of eye health.
Nova Eye Medical Ltd, a leading ophthalmic device company, has achieved several significant milestones. Over the years, the company has made remarkable progress in the field of ophthalmology. Nova Eye Medical Ltd developed and commercialized the iTrack(TM) surgical system, a breakthrough technology for the treatment of glaucoma. This innovative system enables surgeons to access and treat the eye's natural drainage pathway, improving patient outcomes. Nova Eye Medical Ltd has also received regulatory approvals for its iTrack(TM) system in various countries, expanding its global market reach. Moreover, the company has successfully completed clinical trials, proving the safety and efficacy of its products. These extraordinary achievements highlight Nova Eye Medical Ltd's dedication to advancing eye care and improving patients' quality of life.
Nova Eye Medical Ltd is primarily present in Australia and New Zealand.
Nova Eye Medical Ltd represents a commitment to innovation, excellence, and patient-centered care. As a leading player in the ophthalmic industry, the company strives to enhance the quality of life for individuals suffering from vision-related conditions. Nova Eye Medical Ltd's corporate philosophy revolves around advancing medical technologies to deliver safe, effective, and reliable solutions for eye care professionals and their patients. With a strong focus on research and development, the company aims to improve diagnostics, treatment, and management of eye diseases. Nova Eye Medical Ltd stands as a trusted and forward-thinking partner in the pursuit of better eye health outcomes.
Analysts currently set an average price target of 0.51 AUD for the Nova Eye Medical stock (median: 0.51 AUD), implying +264.3 % versus the latest price. The consensus is based on 6 analyst ratings.
6 analysts currently rate the Nova Eye Medical stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Nova Eye Medical to generate revenue of 34.60 M AUD and earnings per share of -0.02 AUD.
Converted at the current exchange rate, the Nova Eye Medical share trades at 0.09 EUR (0.14 AUD).
The Nova Eye Medical share (EYE.AX) is listed on 2 stock exchanges, including: ASX (EYE.AX).
Nova Eye Medical Ltd is a leading company in ophthalmology based in Australia. The business model includes various divisions such as the development, manufacturing, sales, and marketing of innovative medical devices used for the diagnosis and treatment of eye diseases. The company aims to improve the quality of medical care and provide patients with a better quality of life. The first products of Nova Eye Medical Ltd focus on the field of glaucoma treatment. This includes the iTrack™ system, which allows for minimally invasive glaucoma surgery. This system is particularly suitable for patients for whom drug therapy is not sufficient or previous surgical procedures have resulted in risks or side effects. iTrack™ is a flexible catheter system that is inserted into the Schlemm's canal with low pressure and selectively reopens fine drainage channels. This can permanently lower intraocular pressure and positively influence the progression of the disease. Another product of Nova Eye Medical Ltd is the CO₂ laser system. This technology is used in the treatment of retinal diseases and provides a precise and effective therapy option that enables patients to recover quickly. With this system, ophthalmologists can deliver microscopically small laser spots to treat abnormalities of the retina. The CO₂ laser system is characterized by its high precision and minimizes the risk of complications during the procedure. A third important business area of Nova Eye Medical Ltd is the marketing and distribution of products from other manufacturers. The company has formed partnerships with leading ophthalmic device and accessory manufacturers worldwide. This allows customers of Nova Eye Medical Ltd to access a wide range of products and improve and optimize their current treatment systems and processes. Nova Eye Medical Ltd is focused on developing and providing the latest technologies and advanced medical devices and procedures to improve the lives of patients. The company invests in research and development and works closely with ophthalmologists and clinics around the world to support the needs and requirements of patients. Overall, Nova Eye Medical Ltd offers its customers a comprehensive range of products and services in the field of ophthalmology. The company aims to provide its customers with a perfect combination of quality, reliability, and service. With its industry-leading products and professional support, Nova Eye Medical Ltd is a trusted partner for ophthalmologists and clinics worldwide.
The expected revenue of Nova Eye Medical is 34.60 M AUD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Nova Eye Medical is -3.96 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Nova Eye Medical is currently -8.75. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Nova Eye Medical stock.
The price-to-sales ratio (P/S) of Nova Eye Medical is currently 1.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Nova Eye Medical stock.
The Eulerpool Quality Score for Nova Eye Medical is 2/10.
The ISIN of Nova Eye Medical is AU0000094252. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Nova Eye Medical is A2P8CK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Nova Eye Medical is EYE.AX. The ticker symbol is used to trade Nova Eye Medical shares on the stock exchange.
The current dividend yield of Nova Eye Medical is 2.07 %.
Nova Eye Medical paid dividends every year for the past 0 years.
Nova Eye Medical is assigned to the 'Health' sector.
To receive the latest dividend of Nova Eye Medical from amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Nova Eye Medical are distributed in AUD.
Nova Eye Medical stock
Nova Eye Medical Peer Group
Nova Eye Medical Ticker
Nova Eye Medical FIGI
All fundamentals and in-depth analysis of Nova Eye Medical
Our stock analysis for Nova Eye Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nova Eye Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.